araag2/HINT huggingface dataset:
Clinical trial NCT00231387 (phase 3, status: completed)
Conditions: non-insulin-dependent diabetes mellitus
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: rosiglitazone
SMILES: CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1
Eligibility criteria:

        Inclusion criteria:

          -  Type 2 diabetes.

          -  Co-existing vascular disease.

          -  At least 6 months of statin or fibrate therapy.

          -  HbA1c <10% at screening and with at least one atheromatous plaque causing 10-95%
             narrowing of the internal carotid artery.

        Exclusion criteria:

          -  Patients with >2 concomitant oral anti-hyperglycaemic agents within 3 months of
             screening.

          -  Previous exposure to a thiazolidinedione.

          -  History of chronic insulin use.

          -  Use of investigational drug within 30 days.

          -  Systolic blood pressure (bp) > 170 mmHg or diastolic bp >100 mmHg.

          -  Severe or unstable angina.

          -  History of: gangrene, TIA, stroke, hepatic disease, alcohol or drug abuse, surgery of
             the carotid arteries or claustrophobia.
Clinical trial NCT00133185 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: telmisartan 40 mg/hydrochlorothiazide 12.5 mg, losartan 50 mg/hydrochlorothiazide 12.5 mg
SMILES: CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Eligibility criteria:

        Inclusion Criteria:

          1. Mild to moderate hypertension as defined by a morning mean(>95 and <115mmHg) of two
             diastolic blood pressure measurements (DBP) after 5 min in the sitting position
             following a minimum 2-week placebo run in phase.Mean sitting systolic blood pressure
             (SBP) must be >140 and <200mmHg. The mean DBP and SBP values are calculated as the
             mean of the two sitting measurements taken 2 min apart just before the drug intake.

          2. Male or female between 20 to 80 years old

          3. Ability to provide written informed consent.

        Exclusion Criteria:

          1. Patients are still taking more than three anti-hypertensives at the screening visit

          2. Pre-menopausal women

          3. Known or suspected secondary hypertension

          4. Mean sitting DBP<95mmHg and/or mean sitting SBP > 200mmHg at the end of placebo run-in
             phase

          5. Hepatic and/or renal dysfunction

          6. Known bilateral renal artery stenosis, patient with a solitary kidney, post renal
             transplant

          7. Known NYHA functional class Chronic Heart Failure (CHF) III, IV

          8. Unstable angina, myocardial infarction, cardiac surgery or stroke within the preceding
             six months

          9. Post-Transluminal Coronary Angioplasty(PTCA) within the preceding three months

         10. Sustained ventricular tachycardia, atria fibrillation, second or third degree AV
             block, VPC or APC (>10% of heart rate) or other clinically relevant cardiac arrhythmia
             as determined by the clinical investigator

         11. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant
             stenosis of aortic or mitral valve.

         12. Once documented evidence by ophthalmological examination of significant retinal
             haemorrhages/ exudates

         13. Clinically significant sodium depletion as defined by serum sodium level less than 130
             mmol/L

         14. Clinically significant hyperkalemia as defined by serum potassium level >5.5 mmol/L

         15. Non-insulin dependent DM poorly controlled whicih is defined as HbA1c>8% twice
             consecutively within 6 months and/or AC blood sugar>180 mg/dl.

         16. Insulin Dependent Diabetes Mellitus

         17. Chronic administration of oral anticoagulants and/or digoxin within the past 6 months.

         18. Known drug or alcohol dependency

         19. Administration of medication known to affect blood pressure, except medication allowed
             by the protocol

         20. Angioedema with ACE inhibitors

         21. Use of nitrates
Clinical trial NCT00482729 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin phosphate (+) metformin hydrochloride, metformin
SMILES: CN(C)C(=N)NC(N)=N, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has type 2 diabetes mellitus

          -  Patient is greater than or equal to 18 and less than or equal to 78 years of age on
             the day of signing the consent

          -  Patient has Hb1Ac greater than or equal to 7.5% and is appropriate for oral therapy

          -  Patient has not been on any antihyperglycemic agent (AHA) in the last 4 months

          -  Patient is a male, or a female who is unlikely to conceive

        Exclusion Criteria:

          -  Patient has type 1 diabetes mellitus or history of ketoacidosis
Clinical trial NCT01110902 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: agomelatine (ago178c), placebo
SMILES: COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with diagnosis of MDD, single or recurrent episode, according to DSM-IV
             criteria.

          -  Current episode ≥4 weeks.

          -  CGI-Severity score ≥4 at Screening and Baseline.

        Exclusion Criteria:

          -  History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating
             disorder (current or during previous one year), obsessive-compulsive disorder.

          -  Any other current Axis I disorder other than MDD which is the focus of treatment.

          -  Substance or alcohol abuse in the last 30 days, dependence in the last 6 months.

          -  Concomitant psychotropic medication, including herbal preparations and melatonin.

          -  Psychotherapy of any type.

          -  Prior exposure to agomelatine.

          -  Female patients of childbearing potential who are not using effective contraception.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01206972 (phase 3, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: rivaroxaban (bay59-7939), rivaroxaban (bay59-7939), rivaroxaban (bay59-7939), enoxaparin
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients aged 20 years or above

          -  Patients undergoing elective TKR (the first replacement of the applicable knee joint)

          -  Patients' written informed consent to participation after receiving detailed verbal
             and written information on any study specific procedures in advance

        Exclusion Criteria:

          -  Planned, staged major orthopedic surgery within 3 months prior to elective TKR or
             during this study

          -  History of clinically significant active bleeding (e.g. intracranial bleeding,
             gastrointestinal bleeding*), or high bleeding risk

             *: within 3 months prior to elective TKR for gastrointestinal bleeding

          -  Subjects with hepatic disease which is associated with coagulopathy leading to a
             clinically relevant bleeding risk

          -  Severe impaired renal function (CLCR calculated by Cockcroft-Gault formula: <30
             mL/min)

          -  Conditions prohibiting bilateral venography (e.g. amputation of 1 leg, allergy to
             contrast media)

          -  Ongoing anticoagulant therapy (e.g. warfarin, heparins and Factor Xa inhibitors other
             than study medication) that cannot be stopped (in the opinion of the investigator/sub
             investigator)

          -  Subjects for whom epidural catheters are expected to be left in for longer than 18
             hours post-operatively

          -  Planned intermittent pneumatic compression during treatment period.
Clinical trial NCT00224523 (phase 3, status: completed)
Conditions: rhinitis, allergic, perennial
ICD codes: J30.0, J31.0, J30.89, J30.9, A50.05, J30.2, J30.1
Drugs: gw685698x, mometasone furoate
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion criteria:

          -  History of perennial allergic rhinitis of 2 years, with a documented positive allergen
             test to an appropriate allergen.

          -  Female patients of child-bearing potential must be willing to consistently and
             correctly use an acceptable method of birth control.

        Exclusion criteria:

          -  Patients who require certain medications for their allergy.

          -  Patients with serious medical problems.
Clinical trial NCT00418145 (phase 3, status: terminated)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: megadose oral methylprednisolone, iv methylprednisolone
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C
Reason stopped: 
    low enrollment - data was not analyzed for this study
  
Eligibility criteria:

        Inclusion Criteria:

          -  Between the ages of 18 and 50 years, inclusive.

          -  Acute symptomatic exacerbation of MS present for great than 24 hours and less than or
             equal to 7 days at entry with new or worsening symptoms, and with signs referable to
             the symptoms; in the absence of a fever or active infection.

          -  Diagnosis of a relapsing form of multiple sclerosis before randomization as determined
             by Poser or McDonald Criteria.

          -  Expanded disability status scale (EDSS) score between 2 and 6.5, inclusive at entry.

          -  Episodes include study neurologist or neuro-ophthalmologist diagnosed: acute optic
             neuritis, cerebellar, brainstem dysfunction, myelitis, focal cerebral, and/or
             definitive focal sensory dysfunction.

          -  New objective clinical finding other than a sensory exacerbation, or bowel/bladder
             signs alone. Sensory deficits alone will not qualify except for optic neuritis.

          -  Subjects may continue on their current immunomodulating therapy (such as interferons
             or glatiramer acetate) throughout the course of the study. Women who become pregnant
             after the 5-day treatment of steroids should discontinue immunomodulatory treatment.

          -  Understand and sign written informed consent prior to any testing under this protocol,
             including screening tests and evaluations that are not considered part of the
             subject's routine care.

        Exclusion Criteria:

          -  Any patients treated with systemic corticosteroid use within one month of the index
             episode at screening.

          -  Prior use of immunosuppressive treatments within 90 days of index episode
             (mitoxantrone, azathioprine, IVIg) or plasmapheresis.

          -  Any patient who is pregnant or breastfeeding.

          -  Unable to perform the Multiple Sclerosis Functional Composite consisting of: Timed
             25-Foot Walk, 9-Hole Peg Test, and Paced Auditory Serial Addition Test (3 second).

          -  Peripheral or cranial neuropathy as sole problem of acute episode.

          -  History of any significant cardiac, gastrointestinal, hepatic, pulmonary, or renal
             disease; immune deficiency; or other medical conditions that would preclude
             corticosteroid therapy.

          -  Primary Progressive Multiple Sclerosis (PPMS).

          -  Previous participation in this study.
Clinical trial NCT01195662 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, placebo matching dapagliflozin
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent

          -  Males and females, 18 to 89 years old, with type 2 diabetes with inadequate glycemic
             control HbA1c between 7-10.5% and uncontrolled hypertension Systolic Blood Pressure
             (SBP) 140-165 and Diastolic Blood Pressure (DBP) 85-105

          -  Subjects must have a mean 24 hr blood pressure ≥ 130/80 determined by Ambulatory Blood
             Pressure Monitoring (ABPM) within 1 week prior to Day 1 visit

          -  Stable dose of oral antidiabetic agent (OAD) for at least 6 weeks [12 wks for
             Thiazolidinedione (TZD)] or a stable daily dose of insulin, as a monotherapy or in
             combination with another OAD, for 8 weeks, and a stable dose of ACEI or ARB and 1
             additional antihypertensive medication for at least 4 weeks

          -  C-peptide ≥ 0.8 ng/mL

          -  Body Mass Index ≤ 45.0 kg/m2

          -  Serum creatinine < 1.50 mg/dL for men or < 1.40 mg/dL for women

        Exclusion Criteria:

          -  Aspartate aminotransferase (AST) and /or Alanine aminotransferase (ALT) > 3.0*upper
             limit of normal (ULN)

          -  Serum total bilirubin ≥ 1.5*ULN

          -  Creatinine kinase > 3*ULN

          -  Symptoms of severely uncontrolled diabetes

          -  History of malignant or accelerated hypertension

          -  Currently unstable or serious cardiovascular, renal, hepatic, hematological,
             oncological, endocrine, psychiatric, or rheumatic diseases
Clinical trial NCT01584232 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ly2189265, insulin glargine, sulfonylureas (su), biguanide (bg)
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, COC1=CC2=C(C=C1)C(C)(C)C(=O)N(CCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1)C2=O, NC(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Participants who have had a diagnosis of type 2 diabetes mellitus for at least 6
             months before screening

          -  Participants who have been taking sulfonylurea (glibenclamide, gliclazide, or
             glimepiride) and/or biguanide (metformin or buformin). The dose of the drug(s) during
             the 8 weeks before screening must be stable

          -  Participants who have a qualifying glycosylated hemoglobin (HbA1c) value of 7.0% to
             10.0% at screening

          -  Participants who have a body mass index (BMI) of 18.5 to 35.0 kilograms per meter
             squared (kg/m^2)

        Exclusion Criteria:

          -  Participants who have a diagnosis of type 1 diabetes

          -  Participants who have previously been treated with any other glucagon-like peptide 1
             (GLP-1) analog

          -  Participants who have received therapy with an alpha-glucosidase inhibitor (a-GI),
             thiazolidinedione (TZD), glinide, or dipeptidyl peptidase-IV (DPP-IV) inhibitor within
             3 months before screening

          -  Participants who have been currently taking insulin or have had previous insulin
             treatment within 3 months before screening

          -  Participants who have obvious clinical signs or symptoms of pancreatitis, a history of
             chronic pancreatitis, or acute pancreatitis at screening, as determined by the
             investigator. Participants who have a serum amylase concentration ≥ 3 times the upper
             limit of the reference range and/or a serum lipase concentration ≥ 2 times the upper
             limit of the reference range, as determined by the central laboratory at screening

          -  Participants who have self or family history of medullary C-cell hyperplasia, focal
             hyperplasia, or medullary thyroid carcinoma (MTC)
Clinical trial NCT00325546 (phase 3, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: rimonabant (sr141716), placebo
SMILES: CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Body mass index (BMI)> 25 kg/m²

        Exclusion Criteria:

          -  Absence of stable weight (variation < 5 kg) within three months prior to screening
             visit),

          -  Absence of effective contraceptive method for females of childbearing potential,

          -  Presence of treated or untreated type 1 or type 2 diabetes,

          -  Systolic blood pressure > 165 mm Hg and/or diastolic blood pressure > 105 mm Hg on 2
             consecutive visits from the screening to the inclusion visit,

          -  Presence of secondary hypertension,

          -  Patients with conditions/concomitant diseases making them non evaluable for the
             primary efficacy endpoint (presence of any clinically significant endocrine disease
             according to the Investigator, obesity of known endocrine origin...)

          -  Presence of any severe medical or psychological condition or chronic
             conditions/infections that in the opinion of the Investigator would compromise the
             patient's safety or successful participation in the study,

          -  Presence of any clinically significant abnormality according to the Investigator on
             the ECG performed on the inclusion visit.

          -  Presence or history of cancer within the past five years with the exception of
             adequately treated localized basal cell skin cancer or in situ uterine cervical
             cancer.

          -  Related to previous or concomitant medications :

               -  Drugs affecting weight (e.g., sibutramine, orlistat, herbal preparations, etc).

               -  Antidiabetic drugs.

          -  Related to laboratory findings:

               -  Positive test for hepatitis B surface antigen and/or hepatitis C antibody.

               -  Abnormal TSH level (TSH > ULN or < LLN).

               -  Positive urine pregnancy test.
Clinical trial NCT00506441 (phase 3, status: completed)
Conditions: chronic kidney disease, dialysis, hyperphosphatemia
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: mci-196, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, and is >=18 years old

          -  Stable hemodialysis or peritoneal dialysis

          -  Subjects has Stable phosphate control

          -  Subjects on Stabilized phosphorus diet

          -  Subjects undergoing regular dialysis treatment

          -  Female and of child-bearing potential have a negative serum pregnancy test.

          -  Male subjects must agree to use appropriate contraception.

        Exclusion Criteria:

          -  Current clinically significant medical comorbidities, which may substantially
             compromise subject safety, or expose them to undue risk, or interfere significantly
             with study procedures and which, in the opinion of the Investigator, makes the subject
             unsuitable for inclusion in the study.

          -  serum albumin level < 3.0g/dL

          -  PTH level > 1000pg/mL

          -  Hemoglobin level < 8mg/dL

          -  A History of significant gastrointestinal motility problems

          -  Biliary obstruction or proven liver dysfunction

          -  A positive test for hepatitis B surface antigen, hepatitis C antibody or HIV 1 and 2
             antibodies

          -  A clinically significant severe lactose intolerance or sensitivity

          -  A history of substance or alcohol abuse within the last year.

          -  Seizure disorders

          -  A history of drug or other allergy

          -  using cholestyramine, colestipol or colesevelam

          -  Schedule to receive a kidney transplant within the next 6 months

          -  Participation in a clinical study with any experimental medication in the last 30 days
             or an experimental biological product within the last 90 days prior to signing of
             informed consent
Clinical trial NCT00086359 (phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: abacavir sulfate, lamivudine, and zidovudine, lamivudine/zidovudine, lopinavir/ritonavir
SMILES: CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, OC(=O)[C@@H]1CCCN1
Eligibility criteria:

        Note: The pharmacokinetics testing portion of this study has been discontinued in Version
        2.0 of this protocol.

        Inclusion Criteria for Mothers:

          -  HIV infected

          -  Between the 12th and 30th week of pregnancy

          -  Intend to continue pregnancy

          -  Viral load less than 55,000 copies/ml within 30 days of study entry

          -  CD4 count greater than 350 cells/ml within 30 days of study entry

          -  Have not previously taken anti-HIV medications (women who have taken 8 weeks or fewer
             of zidovudine are still eligible) OR have taken anti-HIV medication but have been off
             treatment for more than 180 days

          -  Intend to stop taking anti-HIV medications after pregnancy

          -  Willing to have her infant tested for HIV

          -  Parent or guardian willing to provide informed consent, if applicable

          -  Have access to a participating site and are willing to be followed for the duration of
             the study

        Exclusion Criteria for Mothers:

          -  Chemotherapy for active cancer

          -  Active opportunistic infection or severe medical condition within 14 days of study
             entry

          -  Chronic diarrhea within 1 month of study entry or unresolved acute diarrhea within 7
             days of study entry

          -  Certain abnormal laboratory values

          -  Diabetes mellitus when not pregnant. Participants who have gestational diabetes are
             not excluded.

          -  Current alcohol or other substance abuse that, in the opinion of the investigator, may
             interfere with the study

          -  Acute hepatitis within 90 days of study entry

          -  Major birth defects in infant

          -  Severe skin disorder (e.g., eczema or psoriasis) requiring systemic treatment

          -  Require certain medications

          -  Medical condition that may, in the opinion of the investigator, interfere with the
             study

          -  Intend to breastfeed